Hong Kong SAR

Beijing Capital Land has set the ball rolling for a three tranche rights issue, eyeing around $361.5m from a deal combining its offshore and domestic shares.

Health and Happiness International Holdings, a China-based supplier of paediatric nutritional and baby care products, has increased the size of its loan to $675m on strong demand.

Venus Medtech (Hangzhou), a Chinese biotechnology company, has wrapped up its Hong Kong IPO at the top end of guidance, raking in HK$2.6bn ($311.1m).

JS Global Lifestyle Co, a Hong Kong-based small appliance manufacturer, has started taking orders for its second attempt at a listing, launching bookbuilding on Monday at a fixed price.

Poly Property Development has launched a roadshow for its Hong Kong IPO, with Singapore's sovereign wealth fund GIC throwing its weight behind the company.

In this round-up, Chinese exports shrank in November while imports rose unexpectedly, the China Banking and Insurance Regulatory Commission (CBIRC) will lift foreign ownership caps on life insurance companies to 51%, and the Mainland will waive import tariffs on US soybeans and pork.

Times Neighborhood Holdings is set to hit the market with its Hong Kong IPO next week, according to a source close to the deal.

In this round-up, conflicting trade war headlines confuse the market, Huawei sues the Federal Communication Commission amid public relations troubles at home and the People’s Bank of China (PBoC) signs a three year bilateral currency swap agreement with the Monetary Authority of Macao.

China Merchants Commercial Real Estate Investment Trust has raised HK$2.6bn ($327.6m) from its IPO, breaking a six-year drought of Reit listings in Hong Kong.

China Bohai Bank has begun working with four Chinese banks on a multi-billion-dollar IPO expected in Hong Kong next year, according to a source familiar with the matter.

China YuHua Education pocketed HK$2.02bn ($258.5m) from a convertible bond this week to buy back its outstanding CB, printing a deal that was tailored for hedge funds, writes Jonathan Breen.

Akesobio, a Chinese biopharmaceuticals company, filed a draft prospectus for an IPO with Hong Kong’s stock exchange on Tuesday.